Buprenorphine/naloxone and methadone effectiveness for reducing craving in individuals with prescription opioid use disorder: Exploratory results from an open-label, pragmatic randomized controlled trial

Original research
by
McAnulty, Christina et al

Release Date

2022

Geography

Canada

Language of Resource

English

Full Text Available

Yes

Open Access / OK to Reproduce

Yes

Peer Reviewed

Yes

Objective

We compared the effectiveness of BUP/NX flexible model of care relative to methadone for craving reduction in individuals with prescription-type opioid use disorder (POUD).

Findings/Key points

Compared to the standard methadone model of care, flexible take-home dosing of BUP/NX was associated with lower craving in individuals with POUD.

Design/methods

Data from a multicentric, pragmatic, 24-week open-label randomized controlled trial (n=272)

doi.org

Keywords

Substitution/OAT
Carries/take-home doses